Genzyme Restart Won’t Hobble Shire’s 2012 Prospects, Shire’s Gregoire Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Shire expects only a gradual pick up of competitive pressure from Genzyme's resumption of Fabrazyme manufacturing, with the double-digit growth of revenues in 2011 set to be replicated in 2012.